BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15880742)

  • 1. Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: possible relevance to the effects of mGlu5R blockade in Parkinson's disease.
    Domenici MR; Potenza RL; Martire A; Coccurello R; Pèzzola A; Reggio R; Tebano MT; Popoli P
    J Neurosci Res; 2005 Jun; 80(5):646-54. PubMed ID: 15880742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Permissive role of adenosine A2A receptors on metabotropic glutamate receptor 5 (mGluR5)-mediated effects in the striatum.
    Domenici MR; Pepponi R; Martire A; Tebano MT; Potenza RL; Popoli P
    J Neurochem; 2004 Sep; 90(5):1276-9. PubMed ID: 15312183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenosine A2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N-methyl-D-aspartate effects.
    Tebano MT; Martire A; Rebola N; Pepponi R; Domenici MR; Grò MC; Schwarzschild MA; Chen JF; Cunha RA; Popoli P
    J Neurochem; 2005 Nov; 95(4):1188-200. PubMed ID: 16271052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-DOPA-induced dyskinesias.
    Marin C; Bonastre M; Aguilar E; Jiménez A
    Synapse; 2011 Oct; 65(10):1080-6. PubMed ID: 21484883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease.
    De Leonibus E; Managò F; Giordani F; Petrosino F; Lopez S; Oliverio A; Amalric M; Mele A
    Neuropsychopharmacology; 2009 Feb; 34(3):729-38. PubMed ID: 18704096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
    Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors.
    Lea PM; Movsesyan VA; Faden AI
    Br J Pharmacol; 2005 Jun; 145(4):527-34. PubMed ID: 15821750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist in 6-hydroxydopamine partially lesioned rats reverses abnormal firing of dopaminergic neurons.
    Chen L; Zhang QJ; Liu J; Wang S; Ali U; Gui ZH; Wang Y
    Brain Res; 2009 Aug; 1286():192-200. PubMed ID: 19545547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment.
    Picconi B; Pisani A; Centonze D; Battaglia G; Storto M; Nicoletti F; Bernardi G; Calabresi P
    Brain; 2002 Dec; 125(Pt 12):2635-45. PubMed ID: 12429591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist produces anxiolytic-like effects and reverses abnormal firing activity of projection neurons in the basolateral nucleus of the amygdala in rats with bilateral 6-OHDA lesions.
    Chen L; Liu J; Ali U; Gui ZH; Hou C; Fan LL; Wang Y; Wang T
    Brain Res Bull; 2011 Feb; 84(3):215-23. PubMed ID: 21255635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors.
    Popoli P; Pèzzola A; Torvinen M; Reggio R; Pintor A; Scarchilli L; Fuxe K; Ferré S
    Neuropsychopharmacology; 2001 Oct; 25(4):505-13. PubMed ID: 11557164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.
    Yamamoto N; Soghomonian JJ
    Neuroscience; 2009 Nov; 163(4):1171-80. PubMed ID: 19660528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective mGluR5 receptor antagonist or agonist provides neuroprotection in a rat model of focal cerebral ischemia.
    Bao WL; Williams AJ; Faden AI; Tortella FC
    Brain Res; 2001 Dec; 922(2):173-9. PubMed ID: 11743947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease.
    Ambrosi G; Armentero MT; Levandis G; Bramanti P; Nappi G; Blandini F
    Brain Res Bull; 2010 Apr; 82(1-2):29-38. PubMed ID: 20100549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease.
    Phillips JM; Lam HA; Ackerson LC; Maidment NT
    Eur J Neurosci; 2006 Jan; 23(1):151-60. PubMed ID: 16420425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of chronic, systemic treatment with metabotropic glutamate receptor 5 antagonist on behavioral activity and neuroprotection in a preclinical rat model of Parkinson's disease].
    Chen L; Liu J; Gui ZH; Wang Y; Xiang L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Jan; 42(1):65-8. PubMed ID: 21355304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preproenkephalin mRNA expression in rat dorsal striatum induced by selective activation of metabotropic glutamate receptor subtype-5.
    Parelkar NK; Wang JQ
    Synapse; 2003 Mar; 47(4):255-61. PubMed ID: 12539198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effects of the mGlu5R antagonist MPEP towards quinolinic acid-induced striatal toxicity: involvement of pre- and post-synaptic mechanisms and lack of direct NMDA blocking activity.
    Popoli P; Pintor A; Tebano MT; Frank C; Pepponi R; Nazzicone V; Grieco R; Pèzzola A; Reggio R; Minghetti L; De Berardinis MA; Martire A; Potenza RL; Domenici MR; Massotti M
    J Neurochem; 2004 Jun; 89(6):1479-89. PubMed ID: 15189351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.